A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.

EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.

Promising advanced kidney cancer pipeline therapies such as JANX008, IPI-549, Belzutifan, XmAbA 808, XL092, VB10.NEO, Savolitinib, RC198, NKT2152, NGM707, MEDI5752, ADI-270, ALLO 316, KO 2806, TT ...

The approval makes belzutifan the first agent indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI. The oral hypoxia-inducible factor (HIF)-2 alpha ...

Key Takeaways Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain ...

BOSTON — AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA ® (tivozanib) for the treatment of adults with relapsed or refractory ...

Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tum ...

Health Canada has approved a new drugfor advanced kidney cancer, the first new treatment option for the disease in more than a decade. Renal cell carcinoma is the most common form of kidney cancer ...